Eli Lilly and Company (LLY) and Walmart (WMT) announced a collaboration to expand access to direct-to-consumer pricing for Zepbound single-dose vials available through LillyDirect. Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. LillyDirect’s direct-to-consumer pricing, or self-pay pricing, offers a 50% or greater discount compared to the list price of other incretin medicines for obesity. Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay. Patients with a valid, on-label prescription can access Zepbound vials directly without using insurance. The collaboration with Walmart expands convenient access to Zepbound, especially for those who prefer the ease of pickup at their local Walmart pharmacy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Nvidia Stock (NVDA) Hits All-Time High after Barrage of AI and Supercomputing Deals
- Lilly partners with Nvidia to build AI supercomputer, medicine discovery
- Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital
- Jim Cramer Says One Stock Is Poised to Hit $1 Trillion Soon — Can You Guess Which?
- Eli Lilly’s New Study on Pirtobrutinib: A Long-Term Safety Evaluation